NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $7.56 +0.06 (+0.80%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Enanta Pharmaceuticals Stock (NASDAQ:ENTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enanta Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.37▼$7.6250-Day Range$5.05▼$7.9552-Week Range$4.09▼$17.24Volume156,827 shsAverage Volume282,747 shsMarket Capitalization$161.63 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingModerate Buy Company OverviewEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Read More… Enanta Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreENTA MarketRank™: Enanta Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 227th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.65) to ($4.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.59% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 8.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.11 Percentage of Shares Shorted12.59% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 8.09%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.81 News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.89% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Stock News HeadlinesEnanta Pharmaceuticals, Inc. (ENTA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comEnanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to "Hold" at Wall Street ZenJune 23, 2025 | americanbankingnews.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.June 30 at 2:00 AM | Porter & Company (Ad)FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)June 11, 2025 | finance.yahoo.comEnanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C VirusJune 11, 2025 | businesswire.comEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 27, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the ...May 24, 2025 | finanznachrichten.deEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 15, 2025 | uk.finance.yahoo.comSee More Headlines ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $5.75 at the beginning of 2025. Since then, ENTA shares have increased by 31.5% and is now trading at $7.56. View the best growth stocks for 2025 here. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its earnings results on Monday, May, 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by $0.02. The biotechnology company had revenue of $14.93 million for the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 79.83% and a negative net margin of 149.57%. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG). Company Calendar Last Earnings5/12/2025Today6/30/2025Next Earnings (Estimated)8/04/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTA CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees160Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$24.00 Low Stock Price Target$10.00 Potential Upside/Downside+138.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($4.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$116.04 million Net Margins-149.57% Pretax Margin-153.41% Return on Equity-79.83% Return on Assets-26.65% Debt Debt-to-Equity RatioN/A Current Ratio5.29 Quick Ratio5.29 Sales & Book Value Annual Sales$67.64 million Price / Sales2.39 Cash FlowN/A Price / Cash FlowN/A Book Value$6.08 per share Price / Book1.24Miscellaneous Outstanding Shares21,380,000Free Float18,408,000Market Cap$161.63 million OptionableOptionable Beta0.77 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ENTA) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.